首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model
【24h】

Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

机译:基于结构和性能的优化结合在AML细胞接种小鼠异种移植模型中具有良好抗肿瘤功效的选择性FLT3-ITD抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV411 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML (C) 2019 Elsevier Masson SAS. All rights reserved.
机译:FLT3突变是急性髓性白血病(AML)中最常见的遗传突变之一,其与AML患者的整体存活和难治性差也有关。最近,FLT3抑制剂已被批准用于AML疗法。在此,发现了一系列具有吡唑胺支架的新化合物,其显示出针对FLT3-ITD的有效的抑制活性,并针对表达FLT3-ITD的FLT3-ITD和AML细胞的显着选择性。具有最有前途的细胞活性的化合物46阻断了MV4-11细胞系FLT3途径的自磷酸化。此外,还观察到在化合物46处理中从MV411细胞异种移植物模型中提取的肿瘤细胞中观察到P-STAT5的细胞凋亡和下调。在体内MV4-11异种移植物模型中,化合物46在体外在体外和抑制肿瘤生长中的代谢稳定性和抑制肿瘤生长。化合物46对小鼠的内脏显示没有毒性,并且不会降低小鼠的体重减轻。总之,本研究的结果可以向新的FLT3抑制剂发现提供有价值的见解,而且复合46值得进一步发展为治疗AML(C)2019 Elsevier Masson SAS的潜在药物候选者。版权所有。

著录项

  • 来源
  • 作者单位

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

    Henan Univ Chinese Med Sch Pharm Zhengzhou 450046 Henan Peoples R China;

    China Pharmaceut Univ Sch Pharm Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Pharm Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Pharm Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Pharm Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Lab Mol Design &

    Drug Discovery Nanjing 211198 Jiangsu Peoples R China;

    China Pharmaceut Univ State Key Lab Nat Med Nanjing 210009 Jiangsu Peoples R China;

    China Pharmaceut Univ Sch Sci Nanjing 211198 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    FLT3-ITD; Inhibitor; Selectivity; AML;

    机译:FLT3-ITD;抑制剂;选择性;AML;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号